Royalty Pharma plc
RPRX
Rang in aandelen
#875
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a... Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Aandeelprijs
$61.87
Marktkapitalisatie
$27.55B
Verandering (1 dag)
2.65%
Verandering (1 jaar)
68.91%
Land
US
Handel Royalty Pharma plc (RPRX)
Categorie
Healthcare
Dividendrendementgeschiedenis voor Royalty Pharma plc (RPRX)
Het dividendrendement (TTM) van Royalty Pharma plc (aandelsymbool: RPRX) per 2023-12-31 is: 2.85%
Gemiddeld dividendrendement over de afgelopen 5 jaar: 2.37%
Gemiddeld dividendrendement over de afgelopen 5 jaar: 2.37%
Dividendrendementgeschiedenis van Royalty Pharma plc (RPRX) van 2015 tot 2026
Dividendrendement aan het einde van elk jaar (TTM)
| Jaar | Dividendrendement | Wijzigen |
|---|---|---|
| 2026 (TTM) | 1.57% | -52.57% |
| 2024 | 3.31% | 16.14% |
| 2023 | 2.85% | 47.67% |
| 2022 | 1.93% | 11.56% |
| 2021 | 1.73% | -15.61% |
| 2020 | 2.05% | -56.29% |
| 2019 | 4.69% | -9.28% |
| 2018 | 5.17% | 10.94% |
| 2017 | 4.66% | 0.00% |
| 2016 | 0.00% | 0.00% |
| 2015 | 0.00% | 0.00% |
Dividendrendementen (TTM) van vergelijkbare bedrijven of concurrenten
| Bedrijf | Dividendrendement | Land |
|---|---|---|
| 0.00% |
SE
|
|
| 0.00% |
FR
|
|
| 0.00% |
IT
|
|
| 0.00% |
US
|
|
| 2.29% |
HK
|
